Viridian Therapeutics, Inc. Common Stock (VRDN)

Viridian Therapeutics reported Q2 2025 results, highlighting progress in thyroid eye disease treatment with veligrotug, securing FDA Breakthrough Therapy Designation and a $70 million licensing deal with Kissei Pharmaceutical, while experiencing increased research expenses and net losses.

The global ophthalmic disease therapeutics market is projected to grow significantly due to factors like the introduction of innovative treatments, rising disposable incomes, and expanding healthcare infrastructure. The market is segmented by indication, therapies, and distribution channel.

7 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $26.57, a high estimate of $31.00, and a low estimate of $20.00. A decline of 15.38% from the prior average price target is evident in the current average. Understanding Analyst Ratings: A Comprehensive Breakdown The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Richard Law Goldman Sachs Announces Buy $23.00 - Douglas Tsao HC Wainwright & Co. Lowers Buy $27.00 $37.00 Leland Gershell Oppenheimer Lowers Outperform $31.00 $36.00 Kalpit Patel B. Riley Securities Lowers Neutral $20.00 $25.00 Serge Belanger Needham Maintains Buy $30.00 - Kalpit Patel B. Riley Securities Lowers Buy $25.00 $29.00 Serge Belanger Needham Maintains Buy $30.00 $30.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating ...Full story available on Benzinga.com

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Activision Blizzard's stock rallies after court ruling clears a path for Microsoft merger to proceed, Rivian shares fall to snap record 9-day win streak.